Overview
Tesamorelin (Egrifta) is a stabilized GHRH analogue with a genuine FDA approval — for reducing excess visceral abdominal fat in HIV patients with lipodystrophy. That approval makes it unique among the growth hormone peptides: real human trials, real manufacturing standards, real dosing data.
Off-label, it has attracted interest for visceral fat reduction and, more recently, cognitive aging.
How It Works
Tesamorelin is GHRH 1-44 with a trans-3-hexenoic acid modification that protects it from enzymatic breakdown. It binds pituitary GHRH receptors and restores a more youthful, pulsatile pattern of growth hormone release, raising IGF-1 into the upper-normal range.
Visceral fat specificity
Growth hormone preferentially mobilizes visceral adipose tissue — the metabolically dangerous fat around organs — over subcutaneous fat. Trials showed roughly 15-18% visceral fat reduction over 26 weeks, with subcutaneous fat largely untouched.
Key Benefits
Visceral fat reduction — the approved indication, with solid trial data behind it.
Pulsatile GH restoration — works with your physiology rather than overriding it.
Cognitive signals — a notable trial showed improved executive function in older adults with mild cognitive impairment.
Triglycerides and liver fat — modest improvements observed in the HIV lipodystrophy population.
Side Effects & Considerations
The most common trial side effects were injection site reactions, joint pain, peripheral edema and carpal tunnel symptoms — the classic growth hormone excess cluster. IGF-1 monitoring is standard; glucose tolerance can worsen.
Key boundaries
Active malignancy is a contraindication — GH/IGF-1 elevation and cancer do not mix. Effects reverse within months of stopping: visceral fat returns. And while tesamorelin is a legitimate approved drug, using it off-label for physique or anti-aging purposes means either a cooperative physician or the grey market, with the usual caveats for the latter.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Approved (Egrifta) | 2 mg | Once daily subcutaneous | 26+ weeks; effects reverse on stopping | Prescription only. IGF-1 monitoring recommended. Inject into abdomen, rotating sites. |
Warnings
Prescription medication. Contraindicated with active malignancy. Monitor IGF-1 and glucose. Benefits reverse after discontinuation.